Clinical Trial Update: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic/pharmacodynamic safety and tolerability study of dabigatran etexilate in patients with moderate liver impairment compared with individ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatic Insufficiency | Phase 1 | Status: COMPLETED